COMBO I Study — LDL-C Efficacy 75 mg/150 mg (in ASCVD) 

On top of maximally tolerated statins,

PRALUENT® (alirocumab): Powerful LDL-C reduction at the recommended starting dose of 75 mg Q2W*

83% of patients in the COMBO I Study achieved LDL-C goal (<70 mg/dL) at week 8 and did not require up-titration at week 121

Only 17% of patients needed to be up-titrated at week 12 from 75 mg to 150 mg1

  • At week 12: 45% LDL-C reduction with PRALUENT 75 mg vs +1% with placebo
  • ASCVD population: Overall, 84% had clinical ASCVD
View examples of patients with ASCVD

NEXT: PRALUENT LDL-C Efficacy 75 mg/150 mg (vs ezetimibe)

  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.

Download Resources